You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

NSCLC Trial in Worldwide (Afatinib)

Completed
Has Results
  • NSCLC
  • Köln, Germany
  • +4 more
Aug 23, 2022

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors Trial in Miami Beach, Kansas City (ARX788)

Withdrawn
  • HER2 Mutation-Related Tumors
  • HER2 Amplified Solid Tumors
  • Miami Beach, Florida
  • +1 more
Apr 22, 2022

Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • Dnipro, Ukraine
  • +1 more
Jun 17, 2023

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

Not yet recruiting
  • HER2 Mutant Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
Dec 6, 2022

Non Small Cell Lung Cancer Trial in Shanghai (RC48)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jan 26, 2022

Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Guanzhou, China
    SunYat-senU
May 5, 2023

HER2 Gene Mutation Trial in Shanghai (Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin)

Recruiting
  • HER2 Gene Mutation
  • Injection of IAH0968+Gemcitabine+Cisplatin
  • Gemcitabine+Cisplatin
  • Shanghai, China
    Fudan University Affiliated Zhongshan Hospital
Aug 7, 2023

Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

Active, not recruiting
  • Metastatic Cancer
  • HER2 Gene Mutation
  • Neratinib Maleate
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Oct 18, 2023

HER2 Gene Mutation Trial (Injection of IAH0968 + CAPEOX, PLACEBO+CAPEOX)

Not yet recruiting
  • HER2 Gene Mutation
  • Injection of IAH0968 + CAPEOX
  • PLACEBO+CAPEOX
  • (no location specified)
Jan 4, 2023

HER2 Mutation-Related Tumors, HER2 Amplification Trial (ARX788)

Not yet recruiting
  • HER2 Mutation-Related Tumors
  • HER2 Amplification
  • (no location specified)
Aug 23, 2021

Metastatic Breast Cancer Trial (Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Lasofoxifene in combination with abemaciclib
  • Fulvestrant in combination with abemaciclib
  • (no location specified)
Jan 25, 2023

HER2 Insertion Mutation Positive Advanced NSCLC Trial in Changsha (PD-1 Combined With Pyrotinib)

Recruiting
  • HER2 Insertion Mutation Positive Advanced NSCLC
  • PD-1 Combined With Pyrotinib
  • Changsha, Hunan, China
    Hunan Provincal Tumor Hospital
Mar 1, 2022

A NIS of Alpelisib in Combination With Fulvestrant in

Not yet recruiting
  • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
  • Alpelisib
  • Fulvestrant
  • (no location specified)
Aug 9, 2022

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +3 more
  • San Antonio, Texas
  • +1 more
Aug 22, 2022

Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)

Recruiting
  • Advanced Breast Cancer
  • Thalassery, Kerala, India
    Novartis Investigative Site
Nov 21, 2022

Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III, HER2 Gene Mutation Trial in France (pertuzumab +

Active, not recruiting
  • Non Small Cell Lung Cancer Metastatic
  • +2 more
  • pertuzumab + trastuzumab + docetaxel
  • Besançon, France
  • +17 more
Mar 9, 2022

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

Recruiting
  • Pancreatic Adenocarcinoma Metastatic
  • +14 more
  • Boston, Massachusetts
  • +1 more
Dec 6, 2022